#Natera co-founder and executive chairman of the board, Matthew Rabinowitz, PhD, has been named a finalist in the Leadership category for the California Life Sciences (CLS) Pantheon Award. The award recognizes leaders who innovate in life sciences, demonstrating commitment to positive global impact and support for patient-centric initiatives. Winners are selected by public voting now through October 15th. Please cast your vote at https://lnkd.in/eGPkm4xA by selecting the leadership category at the bottom. #PantheonAwards
Natera
生物技术研究
Austin，Texas 136,320 位关注者
We are a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health.
关于我们
Natera? is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build?a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.? Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to?change the management of disease worldwide? Visit?https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/
- 网站
-
https://www.natera.com
Natera的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Austin，Texas
- 类型
- 上市公司
- 创立
- 2004
- 领域
- Non-Invasive Prenatal Testing (NIPT)、Single gene diseases、Preimplantation Genetic Screening (PGS)/Diagnosis (PGD)、Biopsy training、Multi-Disease Carrier Screening、Bioinformatics、Miscarriage testing、Genetic counseling、Non-invasive paternity testing、Genetics、colorectal cancer、Oncology、Transplant、Kidney Transplant、Cancer、Transplant Rejection和ctDNA
地点
Natera员工
动态
-
Up to 30% of breast cancer survivors will face a recurrence, sometimes years after treatment. Our #Signatera test detects molecular residual disease – tiny traces of cancer cells that can remain in the body after treatment and may lead to recurrence. It can detect these signs months before imaging, giving survivors and their cancer care team more time to act. Stay ahead of recurrence – learn how Signatera can support long-term health today. https://lnkd.in/e_ZDnXd9 #BreastCancer
When Danielle’s breast cancer molecular recurrence was detected by Natera's Signatera test, she and her doctor had incentive to act quickly. “I caught it at the molecular level and was able to intervene with treatment,” Danielle shared. Now, she’s celebrating consecutive negative Signatera tests! ?? Hear more about her journey and how Signatera testing can help breast cancer survivors monitor for recurrences: https://ow.ly/bPsJ50TBC3S #BreastCancer #Natera
-
#Natera co-founder and executive chairman of the board, Matthew Rabinowitz, PhD, has been named a finalist in the Leadership category for the California Life Sciences (CLS) Annual Pantheon Awards. This recognition follows his recent honor as R&D Leader of the Year by R&D World. ?? The Pantheon award celebrates California leaders making valuable contributions across the pharmaceutical, biotech and other industries. Winners are selected by public voting, which is open now through October 15th. Cast your vote here: https://ow.ly/TRKX50TBIYj
-
-
Natera转发了
October is #NationalBreastCancerAwarenessMonth, but it's about more than awareness...it's about action. We need everyone to join us in spreading the message -- from advocating for early detection to supporting research and equitable care for all, your voice matters. Follow along with us here all month long or visit komen.org to find out how to join our fight. Because ending breast cancer needs all of us.
-
-
Natera转发了
I previously discussed Natera’s 200+ peer-reviewed papers and transformational moments in healthcare. We are at another such milestone: The release of data from Circulate Japan in simultaneous papers in Nature Medicine and Annals of Oncology. The studies demonstrate a 10x overall survival improvement for Signatera-positive vs. negative colorectal cancer (CRC) patients and that we can at last decipher who should and shouldn’t receive chemotherapy after tumor removal. This technology can potentially save the U.S. healthcare system more than any single drug repricing in the Inflation Reduction Act and save many patients the side-effect and emotional burden of unnecessary chemo. This has already led to updates in the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines, marking a significant shift in global care. Congrats and thanks to the superb team at Natera; we’ve surpassed 85 peer-reviewed publications on Signatera alone. #ColorectalCancer #CancerResearch #CancerTreatment #HealthcareInnovation #CancerGuidelines #MedTech
-
Natera转发了
#NSGC24 Cancer Special Interest Group (SIG) Happy Hour | Driving Hereditary Cancer Testing & Precision Patient Management in Oncology Join Natera on Sept. 19th for a taste of New Orleans and to preview our new hereditary cancer program offerings. Explore customizable gene and panel options, and patient access support with the Natera Empower Hereditary Cancer Test. Learn about the new Hereditary Cancer Alert Program (HCAP) utilizing the Signatera Residual Disease Test (MRD), which increased at-risk patients receiving hereditary cancer testing by 200% in a pilot study. Register here?? https://ow.ly/2uzu50Thx4H #Natera #Oncology #HereditaryCancer
-
-
Natera转发了
#NSGC24 Learning Theater | Katherine Krepkovich, medical science liaison at Natera, will present data from the largest clinical validation study for #FetalRhD to date in the US, with >650 Rh negative pregnant people and confirmation by serology on all newborns. ?? Register here?? https://ow.ly/GWQC50TfOhT #Natera #RhD #NIPT #GeneticCounselor
-
-
“ESMO 2024 will showcase some of our most impactful data in colorectal cancer to-date,” said Minetta Liu, MD, chief medical officer of oncology at Natera. “Notably, we will present an updated analysis from the GALAXY arm of CIRCULATE-Japan with the first prospective read-out of overall survival based on MRD. These findings underscore the potential for Signatera to predict long-term outcomes.” #ESMO24
Natera will present new data on its personalized and tumor-informed molecular residual disease (#MRD) test, Signatera, at the 2024 ESMO - European Society for Medical Oncology Congress taking place Sept. 13-16 in Barcelona, Spain. Presentations include abstracts from the GALAXY arm of the CIRCULATE-Japan trial, along with new data in breast cancer and squamous cell carcinoma of the head and neck. Read more in our press release below. https://ow.ly/YxIY50TiOML #ESMO24 #CancerResearch
Natera to Present New Signatera? Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
natera.com
-
We're looking forward to the National Society of Genetic Counselors Annual Conference later this month. ?? See below for details on our events and presentations, and don't forget to stop by booth 210 to speak with our experts (and get your resume reviewed)! ?? Register for our learning theater and happy hour here: https://ow.ly/s6fu50TgwvX #NSGC24 #Natera #NIPT #RhD #PrecisionMedicine #Oncology #GeneticCounselor Katherine E. Krepkovich, M.S., M.S., C.G.C. Sheetal Parmar Lisa Bush, MS, CGC
-
September brings us into Ovarian/Gynecological Cancer Awareness Month ?? We believe in the importance of empowering healthcare journeys through education, conversations with loved ones, and genetic testing to help ensure as much information as possible is available for patients and care teams to make healthcare decisions. Thanks, Ovarian Cancer Research Alliance for raising awareness about the importance of genetic testing for this community. Visit ocrahope.org/ovcamonth to learn more. #Natera #OVCA #OvarianCancerAwareness #Gynecology #Oncology #CancerAwareness
-